- LYRA Dashboard
-
Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Lyra Therapeutics (LYRA) Financial statements
Company Profile
Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|
Total Revenue | ||||
Cost of Revenue | ||||
Gross Profit | ||||
Gross Profit Margin (%) | ||||
R&D Expense | ||||
SG&A Expense | ||||
Total Operating Expenses | ||||
Operating Income or Loss | ||||
Operating Margin (%) | ||||
Interest Expense | ||||
Total Other Income/Expenses | ||||
Income Before Tax | ||||
Income Tax Expense | ||||
Income from Continuing Ops. | ||||
Net Income | ||||
Net Profit Margin (%) | ||||
Net Income Available to Common Shareholders | ||||
Basic EPS | ||||
Diluted EPS | ||||
Basic Average Shares | ||||
Diluted Average Shares |
Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | |||||||||||||||||||
Cost of Revenue | |||||||||||||||||||
Gross Profit | |||||||||||||||||||
Gross Profit Margin (%) | |||||||||||||||||||
R&D Expense | |||||||||||||||||||
SG&A Expense | |||||||||||||||||||
Total Operating Expenses | |||||||||||||||||||
Operating Income or Loss | |||||||||||||||||||
Operating Margin (%) | |||||||||||||||||||
Interest Expense | |||||||||||||||||||
Total Other Income/Expenses | |||||||||||||||||||
Income Before Tax | |||||||||||||||||||
Income Tax Expense | |||||||||||||||||||
Income from Continuing Ops. | |||||||||||||||||||
Net Income | |||||||||||||||||||
Net Profit Margin (%) | |||||||||||||||||||
Net Income Available to Common Shareholders | |||||||||||||||||||
Basic EPS | |||||||||||||||||||
Diluted EPS | |||||||||||||||||||
Basic Average Shares | |||||||||||||||||||
Diluted Average Shares |
Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|
Current Assets | ||||
Cash & Cash Equivalents | ||||
Marketable Securities | ||||
Receivables | ||||
Inventories | ||||
Other Current Assets | ||||
Total Current Assets | ||||
Non-Current Assets | ||||
Marketable Securities | ||||
PPE Net | ||||
Intangibles inc. Goodwill | ||||
Other Non-Current Assets | ||||
Total Non-Current Assets | ||||
Total Assets | ||||
Current Liabilities | ||||
Accounts Payable | ||||
Deferred Revenues | ||||
Debt, Current | ||||
Accrued Liabilities | ||||
Other Current Liabilities | ||||
Total Current Liabilities | ||||
Non-Current Liabilities | ||||
Deferred Revenues | ||||
Debt, Non-Current | ||||
Other Non-Current Liabilities | ||||
Total Non-Current Liabilities | ||||
Total Liabilities | ||||
Shareholders' Equity | ||||
Common Stock | ||||
Additional Paid-In Capital | ||||
Retained Earnings | ||||
Other Shareholders' Equity | ||||
Total Shareholders' Equity | ||||
Total Liabilities & Shareholders' Equity |
Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Current Assets | |||||||||||||||||||
Cash & Cash Equivalents | |||||||||||||||||||
Marketable Securities | |||||||||||||||||||
Receivables | |||||||||||||||||||
Inventories | |||||||||||||||||||
Other Current Assets | |||||||||||||||||||
Total Current Assets | |||||||||||||||||||
Non-Current Assets | |||||||||||||||||||
Marketable Securities | |||||||||||||||||||
PPE Net | |||||||||||||||||||
Intangibles inc. Goodwill | |||||||||||||||||||
Other Non-Current Assets | |||||||||||||||||||
Total Non-Current Assets | |||||||||||||||||||
Total Assets | |||||||||||||||||||
Current Liabilities | |||||||||||||||||||
Accounts Payable | |||||||||||||||||||
Deferred Revenues | |||||||||||||||||||
Debt, Current | |||||||||||||||||||
Accrued Liabilities | |||||||||||||||||||
Other Current Liabilities | |||||||||||||||||||
Total Current Liabilities | |||||||||||||||||||
Non-Current Liabilities | |||||||||||||||||||
Deferred Revenues | |||||||||||||||||||
Debt, Non-Current | |||||||||||||||||||
Other Non-Current Liabilities | |||||||||||||||||||
Total Non-Current Liabilities | |||||||||||||||||||
Total Liabilities | |||||||||||||||||||
Shareholders' Equity | |||||||||||||||||||
Common Stock | |||||||||||||||||||
Additional Paid-In Capital | |||||||||||||||||||
Retained Earnings | |||||||||||||||||||
Other Shareholders' Equity | |||||||||||||||||||
Total Shareholders' Equity | |||||||||||||||||||
Total Liabilities & Shareholders' Equity |
Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|
Cash Flows from Operating Activities | ||||
Net Income | ||||
Depreciation & Amortization | ||||
Deferred Income Taxes | ||||
Stock Based Compensation | ||||
Accounts Receivable | ||||
Inventory | ||||
Accounts Payable | ||||
Deferred Revenue | ||||
Other Non-Cash | ||||
Operating Cash Flow | ||||
Cash Flows from Investing Activities | ||||
PPE Investments | ||||
Net Acquisitions | ||||
Purchase of Investments | ||||
Sale of Investments | ||||
Other Investing Activity | ||||
Investing Cash Flow | ||||
Cash Flows from Financing Activities | ||||
Debt Issued | ||||
Proceeds from Debt Repayment | ||||
Debt Repayment | ||||
Proceeds from Sale of Equity | ||||
Equity Repurchased | ||||
Dividend Paid | ||||
Other Financing Activity | ||||
Financing Cash Flow | ||||
Cash Position | ||||
Beginning Cash Position | ||||
End Cash Position | ||||
Change in Cash | ||||
Free Cash Flow | ||||
Operating Cash Flow | ||||
Capital Expenditure | ||||
Free Cash Flow |
Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | |||||||||||||||||||
Net Income | |||||||||||||||||||
Depreciation & Amortization | |||||||||||||||||||
Deferred Income Taxes | |||||||||||||||||||
Stock Based Compensation | |||||||||||||||||||
Accounts Receivable | |||||||||||||||||||
Inventory | |||||||||||||||||||
Accounts Payable | |||||||||||||||||||
Deferred Revenue | |||||||||||||||||||
Other Non-Cash | |||||||||||||||||||
Operating Cash Flow | |||||||||||||||||||
Cash Flows from Investing Activities | |||||||||||||||||||
PPE Investments | |||||||||||||||||||
Net Acquisitions | |||||||||||||||||||
Purchase of Investments | |||||||||||||||||||
Sale of Investments | |||||||||||||||||||
Other Investing Activity | |||||||||||||||||||
Investing Cash Flow | |||||||||||||||||||
Cash Flows from Financing Activities | |||||||||||||||||||
Debt Issued | |||||||||||||||||||
Proceeds from Debt Repayment | |||||||||||||||||||
Debt Repayment | |||||||||||||||||||
Proceeds from Sale of Equity | |||||||||||||||||||
Equity Repurchased | |||||||||||||||||||
Dividend Paid | |||||||||||||||||||
Other Financing Activity | |||||||||||||||||||
Financing Cash Flow | |||||||||||||||||||
Cash Position | |||||||||||||||||||
Beginning Cash Position | |||||||||||||||||||
End Cash Position | |||||||||||||||||||
Change in Cash | |||||||||||||||||||
Free Cash Flow | |||||||||||||||||||
Operating Cash Flow | |||||||||||||||||||
Capital Expenditure | |||||||||||||||||||
Free Cash Flow |